Arkansas Research
Little Rock, Arkansas, 72202, United States
NCT Number: NCT00602381
The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate 450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg extended release tablet under fasting conditions using a single-dose, randomized, three-treatment, three-period, six-sequence crossover design.
Looking for future studies?
Notify Me25 year–45 year
All sexes
Interventional
Not applicable
Little Rock, Arkansas, 72202, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline, Three period, Fourteen day washout
Roxane Laboratories
Industry
A Single Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalency Study of 450 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06365021
Bipolar Disorder, Bipolar and Related Disorders
São Paulo, Brazil
View Trial DetailsNCT02481245
Bipolar Disorder, Bipolar and Related Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT03336918
Behavior, Behavioral Symptoms
Cleveland, Ohio, United States
View Trial DetailsNCT04696471
Bipolar Disorder, Bipolar and Related Disorders
Pittsburgh, Pennsylvania, United States
View Trial Details